AbbVie

Open: 147.97 Close: 150.85 Change: 2.88

An AI to read internet: The best strategy to evaluate AbbVie.

This document will help you to evaluate AbbVie without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AbbVie are: AbbVie, revenue, report, net, Inc, result, endpoint, and the …

Concept Map

Semantic Network

Stock Summary

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenos.

Today's Summary

AbbVie beat sales expectations with revenue of $12.23 billion, topping estimates of $13.17 billion. European Commission Approval of RINVOQ for the Treatment of Moderately to Severely Active Crohns Disease. The company avoided a sales cliff.

Today's News

AbbVie reports 9.7% fall in global net revenues for q1 2022. Abbvies immunology portfolio registered global net revenue of $5.58bn during Q1 2023. Abvie chairman and CEO Richard Gonzalez stated: “This year is off to an excellent start, with first-quarter revenues. AbbVie beat sales expectations with revenue of $12.23 billion, topping estimates of $13.17 billion. The company avoided a sales cliff caused by the loss of Humira exclusivity. AbbVie Inc. cites disappointing results from its latest proof-of-concept study of a triplet therapy to treat cystic fibrosis. Decision strengthens the marketplace domination of Vertex Pharmaceuticals Inc. Lawsuit accuses AbbVie of inflating the cost of Humira to levels far out of step with manufacturing costs and in violation of consumer protection laws. Lawsuit alleges Abbvie repeatedly raised the publicly listed price paid by consumers, while offering pharmacy benefit managers lower, undisclosed net prices. AbbVie will announce its first-quarter financial results on Thursday, April 27, 23, before the market opens. European Commission Approval of RINVOQ for the Treatment of Moderately to Severely Active Crohns Disease. AbbVie announces positive top-line results from INSPIRE, a Phase 3 induction study, showing Skyrizi (risankizumab, 1200 mg intravenous (IV), at weeks 0, 4 and 8) met the primary endpoint of clinical remission at week 12, as well as all secondary endpoints in adult patients with moderately to severely active ulcerative colitis. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements. AbbVie Inc. Stock Falls Friday, Underperforms Market. European Commission Approval of RINVOQ(R) for the Treatment of Moderately to Severely Active Crohns Disease. AbbVie stock plunged early Thursday after the pharmaceutical company reported adjusted earnings of $2.46 per share and $3.26 per share. The company reported a quarterly revenue of $15.12 billion and a net profit of $ 2.47 billion. AbbVie announces positive top-line results from INSPIRE, a Phase 3 induction study, showing Skyrizi (risankizumab, 1200 mg intravenous (IV) met the primary endpoint of clinical remission at week 12, as well as all secondary endpoints in adult patients with moderately to severely active ulcerative colitis (UC) The FDA approved expanding the indication of Qulipta. Also dead complex noses belongings protocolspp Trance Colin proble­ joystick AbbVie Inc. (ABBV) earnings report | Seeking Alpha Home Analysis News Market Data Investing Groups Explore Investing Group Find & Compare Top Stocks Top ETFs.

Stock Profile

"AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; and Genentech, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois."

Keywords

The game is changing. There is a new strategy to evaluate AbbVie fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AbbVie are: AbbVie, revenue, report, net, Inc, result, endpoint, and the most common words in the summary are: abbvie, stock, report, market, new, inc, price, . One of the sentences in the summary was: European Commission Approval of RINVOQ for the Treatment of Moderately to Severely Active Crohns Disease. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #abbvie #stock #report #market #new #inc #price.